Jiuwei Cui
Amgen (United States)(US)Jilin University(CN)Anhui Medical University(CN)Chinese Academy of Medical Sciences & Peking Union Medical College(CN)Sichuan University(CN)Jilin Province Tumor Hospital(CN)Nantong Tumor Hospital(CN)Ingenierie des Materiaux polymeres(FR)Amgen (United Kingdom)(GB)First Hospital of Jilin University(CN)Amgen (Switzerland)(CH)National Cancer Center Hospital East(JP)First Bethune Hospital of Jilin University(CN)Fu Wai Hospital(CN)Baidu (China)(CN)Tsinghua University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Cancer Genomics and Diagnostics, Nutrition and Health in Aging
Most-Cited Works
- → Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study(2021)1,051 cited
- → Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial(2020)492 cited
- → A novel FLI1 exonic circular RNA promotes metastasis in breast cancer by coordinately regulating TET1 and DNMT1(2018)470 cited
- → Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors(2020)467 cited
- → Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer(2022)423 cited
- → Mechanisms of Cancer Resistance to Immunotherapy